Introduction: The myelodysplastic syndromes (MDS) are a group of myeloid clonal disorders characterized by morphologic features, including hyper cellular bone marrow, unilineage or multilineage dysplasia and peripheral blood cytopenic. Anemia is the most commonly diagnosed cytopenic symptom in MDS patients. Regular red blood cell (RBC) transfusion is the often needed for the patients’ symptomatic anemia. Transfusion-dependent patient’s undergone tissue iron overload that may frequently be a prominent clinical feature. The purpose of this study was to determine the serum ferritin and iron levels in MDS patients and evaluation the outcome of the treatments received. Methods: In a retrospective study, the clinical and laboratory data were obtained of all patients with MDS referred to the clinic of Namazi hospital in Shiraz during 2017-2018 and analyzed by SPSS software. Results: Of 76 patients who entered the study 48 (62.66%) were males with a mean age of 68.48 ± 9.33 years and 28 (37.34%) were women with a mean age of 70.42 ± 10.97 years. The mean of ferritin serum level among all patients was 601.13 ± 828.29 mg / l which 16 men and 6 women had > 500 mg / l ferritin concentration, and a direct and significant correlation found between male and serum ferritin level. 17.33% of patients received iron chelator. In addition 15 (19.7%) and 6 (8.00%) of patients intake erythropoietin alone or with GM-SCF growth factor, respectively. Conclusion: Considering the relatively low number of studies are employed the hyperferritinemia in MDS patients, the obtained data define the hyperferritinemia incidence in MDS depended transfusion and serum ferritin higher than 1000 mg/dl can help to good prognosis for patient survival.

• Abdussalam-Mohammed, W. (2020). Comparison of Chemical and Biological Properties of Metal Nanoparticles (Au, Ag), with Metal Oxide Nanoparticles (ZnO-NPs) and their Applications. Advanced Journal of Chemistry, Section A: Theoretical, Engineering and Applied Chemistry 3(2, pp. 111-236): 192-210.
• Alessandrino EP, Della Porta MG, Bacigalupo A, Malcovati L, Angelucci E, Van Lint MT, et al. (2010) Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. haematologica 95(3): 476-84.
• Andrews NC (1999) Disorders of iron metabolism. New England Journal of Medicine 341(26): 1986-95.
• Cazzola M, Malcovati L (2005) Myelodysplastic syndromes—coping with ineffective hematopoiesis. N Engl J Med 352(6): 536-8.
• Chee CE, Steensma DP, Wu W, Hanson CA, Tefferi A (2008) Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts. American journal of hematology 83(8): 611-3.
• Dinmohamed AG, Visser O, van Norden Y, Huijgens PC, Sonneveld P, van de Loosdrecht AA, et al. (2014) Trends in incidence, initial treatment and survival of myelodysplastic syndromes: a population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010. European Journal of Cancer 50(5): 1004-12.
• Glauser TA, Sagatys EM, Williamson JC, Burton BS, Berger C, Merwin P, et al. (2013) Current pathology practices in and barriers to MDS diagnosis. Leukemia research 37(12): 1656-61.
• Greenberg PL (2006) Myelodysplastic syndromes: iron overload consequences and current chelating therapies. Journal of the National Comprehensive Cancer Network 4(1): 91-6.
• Greenberg PL Consequences of Iron Overload in Myelodysplastic Syndromes. Journal-Consequences of Iron Overload in Myelodysplastic Syndromes.
• Greenberg PL, Attar E, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ, et al. (2011) Myelodysplastic syndromes. Journal of the National Comprehensive Cancer Network 9(1): 30-56.
• Harvey RD (2010) Myelodysplastic syndromes and the role of iron overload. American Journal of Health-System Pharmacy 67(7_Supplement_2): S3-S9.
• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA: a cancer journal for clinicians 61(2): 69-90.
• Kacimi R, Khouzami K, Abram T, Bejjit L, Bennani MN, Bouachrine M (2020) Electro-Optical and Photovoltaic Properties of Oligothiophene and Derivatives; Experimental and Theoretical Investigations. Chemical Methodologies 4(2. pp. 115-219): 203-219.
• Kikuchi S, Kobune M, Iyama S, Sato T, Murase K, Kawano Y, et al. (2012) Prognostic significance of serum ferritin level at diagnosis in myelodysplastic syndrome. International journal of hematology 95(5): 527-34.
• Li B, Xu Z, Gale RP, Qin T, Zhang Y, Xiao Z (2013) Serum ferritin is an independent prognostic factor in Chinese with myelodysplastic syndromes classified as IPSS intermediate-1. Acta haematologica 129(4): 243-50.
• Malcovati L (2007) Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. Leukemia research 31: S2-S6.
• Malcovati L, Hellström-Lindberg E, Bowen D, Adès L, Cermak J, Del Cañizo C, et al. (2013) Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 122(17): 2943-64.
• Malcovati L, Porta MGD, Pascutto C, Invernizzi R, Boni M, Travaglino E, et al. (2005) Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. Journal of Clinical Oncology 23(30): 7594-603.
• Park S, Sapena R, Kelaidi C, Vassilieff D, Bordessoule D, Stamatoullas A, et al. (2011) Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS. Leukemia research 35(11): 1530-3.
• Popova A. (2019). Oxidative stress and plant deriving antioxidants. Asian Journal of Green Chemistry.
• Porter JB (2001) Practical management of iron overload. British journal of haematology 115(2): 239-52.
• Remacha ÁF, Arrizabalaga B, Villegas A, Durán MS, Hermosín L, de Paz R, et al. (2015) Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications. Annals of hematology 94(5): 779-87.
• Rose EH, Abels RI, Nelson RA, McCullough DM, Lessin L, Johnson R (1995) The use of r‐HuEpo in the treatment of anaemia related to myelodysplasia (MDS). British journal of haematology 89(4): 831-7.
• Roy NB, Myerson S, Schuh AH, Bignell P, Patel R, Wainscoat JS, et al. (2011) Cardiac iron overload in transfusion‐dependent patients with myelodysplastic syndromes. British journal of haematology 154(4): 521-4.
• Sanz G, Nomdedeu B, Such E, Bernal T, Belkaid M, Ardanaz MT, et al. (2008) Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome. Am Soc Hematology.
• Schottenfeld D, Fraumeni Jr JF (2006) Cancer epidemiology and prevention: Oxford University Press.
• Vardiman J (2012) The classification of MDS: from FAB to WHO and beyond. Leukemia research 36(12): 1453-8.
• Waszczuk-Gajda A, Mądry K, Machowicz R, Drozd-Sokołowska J, Stella-Hołowiecka B, Mital A, et al. (2016) Red blood cell transfusion dependency and hyperferritinemia are associated with impaired survival in patients diagnosed with myelodysplastic syndromes: Results from the first Polish MDS-PALG registry. Advances in Clinical and Experimental Medicine 25(4): 633-41.

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.